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Abstract
Background: Even protective ventilation may aggravate or induce lung failure, particularly in preinjured lungs. Thus, new
adjuvant pharmacologic strategies are needed to minimize ventilator-induced lung injury (VILI). Intermedin/Adrenome-
dullin-2 (IMD) stabilized pulmonary endothelial barrier function in vitro. We hypothesized that IMD may attenuate VILI-
associated lung permeability in vivo.
Methodology/Principal Findings: Human pulmonary microvascular endothelial cell (HPMVEC) monolayers were incubated
with IMD, and transcellular electrical resistance was measured to quantify endothelial barrier function. Expression and
localization of endogenous pulmonary IMD, and its receptor complexes composed of calcitonin receptor-like receptor
(CRLR) and receptor activity-modifying proteins (RAMPs) 1–3 were analyzed by qRT-PCR and immunofluorescence in non
ventilated mouse lungs and in lungs ventilated for 6 h. In untreated and IMD treated mice, lung permeability, pulmonary
leukocyte recruitment and cytokine levels were assessed after mechanical ventilation. Further, the impact of IMD on
pulmonary vasoconstriction was investigated in precision cut lung slices (PCLS) and in isolated perfused and ventilated
mouse lungs. IMD stabilized endothelial barrier function in HPMVECs. Mechanical ventilation reduced the expression of
RAMP3, but not of IMD, CRLR, and RAMP1 and 2. Mechanical ventilation induced lung hyperpermeability, which was
ameliorated by IMD treatment. Oxygenation was not improved by IMD, which may be attributed to impaired hypoxic
vasoconstriction due to IMD treatment. IMD had minor impact on pulmonary leukocyte recruitment and did not reduce
cytokine levels in VILI.
Conclusions/Significance: IMD may possibly provide a new approach to attenuate VILI.
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Introduction
Mechanical ventilation (MV) is a life saving treatment without
alternatives in acute respiratory failure, and MV is also employed
following surgery or trauma. One third of all patients in intensive
care units are receiving MV [1]. Notably, even a minimum of
physical forces on lung tissue induced by MV may evoke
ventilator-induced lung injury (VILI), an important undesirable
effect of respirator therapy [2]. Minimization of MV-induced
physical stress by reduction of tidal volumes to 6 ml/kg
significantly improved clinical outcome of mechanically ventilated
patients [3]. However, particularly preinjured lungs are sensitive
for the development of VILI even in the setting of lung-protective
ventilation [4,5]. VILI is characterized by pulmonary inflamma-
tion with liberation of cytokines, recruitment of leukocytes to the
lung and particularly increased lung permeability, resulting in lung
edema, surfactant dysfunction, impaired lung compliance and
deterioration of pulmonary gas exchange [6]. As the necessity to
guarantee sufficient gas exchange frequently limits a further
substantial reduction of tidal volumes and oxygen supply, new
adjuvant pharmacological therapies enhancing pulmonary vascu-
lar barrier function in VILI/acute respiratory distress syndrome
(ARDS) in addition to lung-protective ventilation are needed to
prevent or ameliorate VILI.
We have previously shown that the potent barrier protective
properties of the calcitonin receptor-like receptor (CRLR) agonist
adrenomedullin reduced VILI in different murine VILI models
[7]. Intermedin (IMD), alternatively named adrenomedullin-2, is
an endogenous peptide also signaling via CRLR coupled to the
receptor activity-modifying proteins (RAMP) 2 or 3 [8,9].
Intermedin stabilized endothelial barrier function in vitro and in
an isolated mouse lung model of hydrostatic lung edema [10,11],
and reduced pulmonary leukocyte infiltration in pulmonary
ischemia/reperfusion injury [12]. Further, IMD had protective
effects in cardiac ischemia/reperfusion injury and lowered
systemic blood pressure [8,13,14].
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e35832Pulmonary hyperpermeability and hyperinflammation are hall-
marks of VILI and ARDS, and pharmacologic attenuation of
vascular barrier breakdown in these conditions may be a promising
therapeutic approach to limit VILI in addition to lung protective
ventilation strategies. We hypothesized that the CRLR ligand
IMD has barrier protective effects in a murine model of VILI in
vivo.
In the current study we observed IMD-evoked barrier
stabilization on endothelial cell layers in vitro. In a clinically
relevant mouse model of VILI, continuously infused IMD reduced
VILI-induced pulmonary hyperpermeability without affecting
pulmonary and systemic inflammation. IMD revealed vasodilata-
tory effects on pulmonary vasculature in mouse lungs. Further, the
influence of MV on pulmonary IMD expression and distribution
as well as on expression of the IMD receptor components was
investigated.
Methods
Ethics Statement
Animal experiments were approved by the animal ethics
committee of the Charite ´-Universta ¨tsmedizin Berlin and local
governmental authorities (LAGeSo (Landesamt fu ¨r Gesundheit
und Soziales Berlin), approval ID: G 0100/10).
Transcellular Electrical Resistance (TER) of
Endothelial Cells
Human pulmonary microvascular endothelial cells (HPMVEC)
were purchased from PromoCell (Heidelberg, Germany) and
grown on evaporated gold electrodes, connected to an electrical
cell-substrate impedance system (Applied Biophysics, Troy, NY,
USA). Cells were exposed to 0.01 or 0.1 mM human IMD (1–47,
Phoenix, Burlingame, CA, USA) or solvent and TER values from
each microelectrode were continuously monitored as described
previously [15].
Mice
Female C57Bl/6 mice (8 to 10 weeks; 18 to 20 g; Charles River,
Sulzfeld, Germany) were used.
Mechanical Ventilation and IMD Treatment
As described previously [16] mice were anesthetized by
intraperitoneal injections of Fentanyl (75 mg/kg), Midazolam
(1.5 mg/kg) and Medetomedin (0.75 mg/kg). Repetitively, Fenta-
nyl (16 mg/kg), Midazolam (0.33 mg/kg) and Medetomedin
(0.16 mg/kg) was supplied via an intraperitoneal catheter when
required to guarantee adequate anaesthesia during the observation
period. Body temperature was maintained at 37uC by a temper-
ature-controlled heating pad. After tracheotomy and intubation,
mice were ventilated (MiniVent, Hugo-Sachs-Electronics, March-
Hugstetten, Germany) with 70% oxygen; tidal volume (VT) 7 ml/
kg; respiratory rate (RR) 240 minute
–1; positive end-expiratory
pressure (PEEP) 6 cmH2O. A carotid artery catheter was placed
for blood pressure monitoring and infusion of NaCl 0.9%
containing 100 mmol/l HCO
3– (350 ml/h). There was no
additional fluid support in any conducted experiment. A urinary
catheter was inserted. VT, RR, airway pressure, peripheral oxygen
saturation and urine output were monitored (Pulmodyn, Hugo-
Sachs-Electronics, March-Hugstetten, Germany; MouseOx,
STARRLife-Sciences, Oakmont, PA, USA). After preparation,
a recruitment manoeuvre was performed (airway pressure
35 cmH2O for 5 sec) before respirator settings were adjusted for
6 h to VT 12 ml/kg, RR 120 min
–1, PEEP 2 cmH2O. A second
recruitment manoeuvre was performed 5 min before termination
of the experiment. All mice survived the protocol. At termination
of the experiments mice were sacrificed by exsanguination via the
carotid artery catheter. Blood samples were analyzed for paO2 and
lactate by blood gas analyzer (ABL-800, Radiometer, Copenha-
gen, Denmark). P/F ratio was calculated as paO2/FiO2. Non-
ventilated mice served as controls. Murine IMD (1–47, Phoenix,
Burlingame, CA, USA) (0.025 mg/kg/h) was continuously infused
via the carotid artery catheter starting with onset of ventilation.
Figure 1. IMD improved endothelial barrier function in endothelial cells. HPMVECs grown to confluence on gold microelectrodes to
measure transcellular electrical resistance (TER) were stimulated with 0.01 or 0.1 mM IMD or with solvent. IMD dose dependently improved
endothelial barrier function as displayed by TER increase. (n=6).
doi:10.1371/journal.pone.0035832.g001
VILI and IMD
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e35832Figure 2. Regulation of IMD and its receptor complexes in VILI. Mice were ventilated with a tidal volume of 12 ml/kg for 6 h (6 h vent.). Non
ventilated individuals (NV) served as controls. A) Regulation of IMD, CGRP and RAMP1-3 was quantified by qRT-PCR in the lungs of ventilated (6 h
vent.) and non ventilated mice (NV). (** p,0.01, n=5). B) Immunofluorescence analysis of subpleural peripheral lung. IMD-immunolabelling was
slightly enhanced in ventilated (6 h vent.) compared to non-ventilated mice (NV) while CRLR-immunolabelling did not differ between groups. Tissue
sections depicting NV and 6 h vent groups were processed simultaneously and images were taken at the same exposure time (30 ms for IMD and
150 ms for CRLR).
doi:10.1371/journal.pone.0035832.g002
VILI and IMD
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e35832Figure 3. Pulmonary distribution of IMD and CRLR was not altered in VILI. In non ventilated mice (A) and individuals ventilated with a tidal
volume of 12 ml/kg for 6 h (6 h vent.) (B) IMD- and CRLR-immunolabelling colocalized with CD31-immunoreactivity (arrows), a marker for endothelial
cells. In addition, alveolar macrophages were IMD- and CRLR-positive (arrowheads). (n=5, representative images shown).
doi:10.1371/journal.pone.0035832.g003
VILI and IMD
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Lungs were flushed and snap frozen in liquid nitrogen. Total
RNA was isolated from the lungs using RNeasy mini kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions.
To remove genomic DNA contamination, isolated RNA samples
were treated with 1 U DNase/mg RNA (Invitrogen, Karlsruhe,
Germany) for 15 min at 37uC. One microgram of total RNA was
used in a 20 ml reaction to synthesize cDNA using Superscript H
-
reverse transcriptase (200 U/mg RNA, Invitrogen) and oligo dTs
as primers. Reverse transcription reaction was for 50 min at 42uC.
Real-time quantitative PCR was performed using the I-Cycler IQ
detection system (Bio-Rad, Munich, Germany) in combination
with the IQ SYBR Green Real-Time PCR Supermix (Bio-Rad).
The PCR conditions included initial denaturation in one cycle of
10 min at 95uC followed by 40 cycles of 20 s at 95uC, 20 s at
60uC, and 20 s at 72uC. The relative expressions were calculated
as: 2
-(DCT) 61/mean control 2
-(DCT), where DCT is calculated as:
DCT=CTGOI-CTHKG (GOI: gene of interest, HKG: house
keeping gene). Primer sequences are provided in Table S1.
Immunofluorescent Staining
Immunolabelling for IMD and CRLR immunolabelling was
performed by overnight incubation at room temperature with
previously characterized antibodies [11,17], including double-
labelling with biotinylated rat monoclonal anti-CD31 (1 mg/ml;
clone MEC 13.3, BD Biosciences, Heidelberg, Germany), an
endothelial marker [18], and biotinylated lycopersicon esculentum
(LEA) lectin (1:3200; Vector Laboratories, Burlingame, CA, USA),
a type I alveolar epithelial cell marker [19]. Secondary reagents,
each applied for 1 h, were Cy3-conjugated goat anti-human IgG
F(ab)2 (1:500; Dianova, Hamburg, Germany), Cy3-conjugated
donkey anti-rabbit IgG (1:2000; Dianova), and FITC-conjugated
streptavidin (1:500; Sigma, Deisenhofen, Germany). Optionally,
nuclei were counterstained by adding 0.4 mg/ml 49,6-diamidino-
29-phenylindole-dihydrochloride (DAPI; Sigma) to the secondary
reagent solution.
Lung Permeability
At the end of the experiment BAL and plasma concentration of
previously injected human serum albumin (cHSA) was determined
and permeability was assessed by calculating the cHSA BAL/
Plasma ratio as described previously [16].
Hypoxic Vasoconstriction in Precision Cut Lung
Slices (PCLS)
PCLS were prepared as described previously [20,21]. Briefly,
mice were killed by cervical dislocation and the airways were filled
with 1.5% low melting point agarose. After solidification of the
agarose, the lungs were cut into 200 mm thick slices. The agarose
was removed by incubation of the PCLS in phenolred-free
minimal essential medium (MEM) continuously gassed with 21%
O2,5 %C O 2, 74% N2 for at least 2 h at 37uC. To analyze
Figure 4 IMD reduced pulmonary vascular hyperpermeability
in VILI. Mice were ventilated with a tidal volume of 12 ml/kg for 6 h
and treated with IMD 0.025 mg/kg*h (6 h vent.+IMD) or solvent (6 h
vent). NV = non ventilated mice. Human serum albumin (HSA) was
infused 90 min prior to termination of the experiment. HSA concen-
tration (cHSA) in plasma and BAL were determined. Increased HSA BAL/
plasma ratio indicated microvascular leakage. (*p,0.05, ## p,0.01 vs.
NV, NV n=5, 6 h vent. n=7, 6 h vent. + IMD n=8)
doi:10.1371/journal.pone.0035832.g004
Figure 5. IMD had no impact on oxygenation in VILI. Mice were
ventilated with a tidal volume of 12 ml/kg for 6 h and treated with IMD
0.025 mg/kg*h (6 h vent.+IMD) or solvent (6 h vent). A) Peripheral SpO2
was monitored. B) At the end of the 6 h ventilation period, SpO2 was
not relevantly different between groups. C) After 6 h of MV, the P/F
ratio was not different between groups. (***p,0.001, n=15)
doi:10.1371/journal.pone.0035832.g005
VILI and IMD
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(minimal inner diameter up to 40 mm), PCLS were transferred
into a flow-through superfusion chamber (Hugo Sachs Elektronik,
March, Germany). At the beginning of each experiment the
capability of the vessel to contract in response to the thromboxane
analogue U46619 and to dilate after application of the NO donor
sodium nitroprusside was checked. After washing out these drugs
with normoxic gassed in phenolred-free MEM (21%O2,5 %C O 2,
74% N2) PCLS were incubated with hypoxic gassed medium
(1%O2,5 %C O 2, 94% N2; 0.7 ml/min). After 15 min 500 nM of
murine IMD was added to the hypoxic medium. Pictures of the
artery were taken every 2 min using an inverted microscope
mounted on the superfusion chamber. Changes of the luminal
area of the vessels were evaluated by lining the inner boundaries
by hand. The luminal area at the beginning of the experiment was
defined as 100% and vasoreactivity was expressed as relative
decrease or increase of this area. In the graph shown only the
values obtained for the hypoxic incubation followed by the
Figure 6. IMD mediated pulmonary vasodilation and reversed
hypoxic pulmonary vasoconstriction. A) In precision cut lung slices
(PCLS) hypoxic pulmonary vasoconstriction (HPV) was induced, and the
luminal areas of single intra-acinar pulmonary arteries were continu-
ously analyzed by planimetry. HPV was markedly reduced by 500 nM
IMD (***p,0.001; n=10). B) In isolated ventilated and perfused mouse
lungs the thromboxane agonist U46619 induced a marked elevation of
pulmonary artery pressure (PAP) during constant perfusion flow. PAP
was lowered dose dependently by IMD bolus injection (* p,0.05,
** p,0.01, n=5)
doi:10.1371/journal.pone.0035832.g006
Figure 7. VILI induced pulmonary leukocyte recruitment and
blood leukocytosis were unaffected by IMD treatment. Mice
were ventilated with a tidal volume of 12 ml/kg for 6 h and treated with
IMD 0.025 mg/kg*h (6 h vent.+IMD) or solvent (6 h vent). NV = non
ventilated mice. Leukocytes isolated from bronchoalveolar lavage fluid
(BALF), lung homogenate and blood, respectively, were quantified and
differentiated by flow cytometry (*p,0.05 vs. NV, **p,0.01 vs. NV, NV
n=5, 6 h vent. n=7, 6 h vent. + IMD n=8)
doi:10.1371/journal.pone.0035832.g007
VILI and IMD
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e35832Figure 8. VILI-induced cytokine production was not altered by IMD. Mice were ventilated with a tidal volume of 12 ml/kg for 6 h and treated
with IMD 0.025 mg/kg*h (6 h vent.+IMD) or solvent (6 h vent). NV=non-ventilated mice. A) IL-1b, IL-18, IL-6, KC, MIP-1a, MIP-2, MCP-1, IL12p40 were
detemined in lung homogenate by multiplex assay technique. (*p,0.05 vs. NV, **p,0.01 vs. NV n=8) B) IL-1b, IL-18, IL-6, KC, MIP-1a, MIP-2, MCP-1,
IL12p40 were determined in plasma by multiplex assay technique. (*p,0.05 vs. NV, **p,0.01 vs. NV n=8).
doi:10.1371/journal.pone.0035832.g008
VILI and IMD
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graphic presentation the values obtained at the beginning of
hypoxia were defined as 100%.
Isolated Perfused and Ventilated Mouse Lungs
Lungs were prepared as described [22,23]. Briefly, anesthetized
mice were tracheotomised and ventilated. After sternotomy and
cannulation of left atrium and pulmonary artery, lungs were
perfused with 37uC sterile Krebs-Henseleit hydroxyethylamylo-
pectine buffer (1 mL/min) and ventilated by negative pressure
(Pexp –4.5, Pins –9.0 cm H2O) in a humidified chamber. After
a steady state period of 30 min, the thromboxane receptor agonist
U46619 (3 610
–8 M) was administered to the perfusate, evoking
an increase in pulmonary arterial pressure. Murine IMD was
administered to the perfusate for 30 seconds in 12-min intervals
with IMD concentrations being increased. Maximum pressure
response after IMD administration was determined.
Leukocytes in Lung Tissue, BAL Fluid and Blood
Lungs were flushed. The left lung was digested in RPMI
containing collagenase and DNAse for 1 h. Leukocytes were
extracted by meshing the lung tissue through a cell strainer
(100 mm). BAL cells were isolated by centrifugation of BAL fluid
gained as described above. Lung and BAL leukocytes were
counted by haemocytometer and blood leukocytes were quantified
using TruCount-Tubes. Leukocytes were differentiated by flow
cytometry according to their sidescatter/forward-scatter properties
and CD45, Gr-1 and F4-80 expression (FACSCalibur, BD,
Heidelberg, Germany).
Quantification of Cytokines
Cytokines were quantified from total protein of flushed
homogenized left lungs and from plasma samples (BioRad,
Hercules, CA, USA).
Data Analyses
Data are expressed as mean 6 SEM. For comparison between
groups, Mann-Whitey U-test was used. For the comparison of
continuously measured data between groups, 2-way ANOVA was
applied. P values ,0.05 were considered statistically significant.
Results
IMD Stabilized Endothelial Barrier Function in HPMVECs
Confluent monolayers of HPMVECs stimulated with 0.01 or
0.1 mM IMD showed a dose dependent increase in TER
displaying improved endothelial barrier integrity. This effect
lasted for the whole observation period of 120 min (Fig. 1).
Comparable improvement of barrier function was observed in
primary human umbilical vein endothelial cell monolayers (data
not shown in detail).
Pulmonary RAMP3 mRNA Levels were Down Regulated
in VILI
The impact of mechanical ventilation on endogenous IMD and
its receptors was determined prior to exogenous IMD application.
The influence of mechanical ventilation on the mRNA expression
of IMD and its receptor compounds CRLR, RAMP1-3 as well as
on the CRLR/RAMP1 agonist calcitonin gene-related peptide
(CGRP) was assessed by qRT-PCR. VILI caused down regulation
of pulmonary RAMP3 mRNA levels while the mRNA levels of
IMD, CRLR, CGRP and RAMP1-2 were not affected by MV
(Fig. 2A). IMD and CRLR protein expression and distribution in
lung tissue was not altered by MV.
To investigate the effect of VILI on pulmonary IMD and
CRLR protein expression and distribution in the lungs, immuno-
fluorescence analysis was performed. The IMD specificity of the
employed antibody was validated in preabsorption experiments
(Fig. S1). A trend towards increased pulmonary IMD expression in
VILI was observed (Fig. 2B). CRLR expression was not altered by
MV (Fig. 2B). IMD and CRLR protein were located mainly,
although not exclusively, in alveolar macrophages and in the
pulmonary endothelium, which was confirmed by double staining
of IMD or CRLR and the endothelial marker CD31 (Fig. 3A).
These expression patterns were not altered by MV (Fig. 3B). Co-
labelling with LEA, a marker for type I alveolar epithelial cells,
demonstrated limited colocalization. Instead, large epithelial
stretches without IMD- or CRLR-immunolabelling were evident
(Fig S2).
Exogenous IMD Reduced Pulmonary Hyperpermeability
in VILI
As we had been observing a robust barrier stabilizing effect of
IMD in vitro, and after having characterized the impact of MV on
the endogenous IMD system we aimed to investigate whether
continuously infused IMD protects against VILI induced pulmo-
nary hyperpermeability in mechanically ventilated mice. Trans-
location of human serum albumin (HSA) from the vascular into
the alveolar compartment was quantified after 6 h of MV and
served as a marker for lung permeability. MV provoked a marked
increase of lung vascular permeability, thereby indicating VILI.
Treatment with exogenous IMD significantly reduced VILI-
evoked pulmonary hyperpermeability (Fig. 4). As increased
permeability is the crucial mechanism for the development of
high permeability lung edema in ALI/VILI, pharmacologic
targeting of this major pathomechanism by IMD is promising.
IMD Infusion Lowered Systemic Arterial Blood Pressure
IMD is a vasoactive peptide causing vasodilation in rodents.
Arterial hypotension and consecutive disturbance of the microcir-
culation thus had to be excluded to avoid interference of shock
with VILI and IMD treatment. Mean systemic arterial blood
pressure (MAP) was measured continuously by means of a catheter
in the carotid artery of each ventilated individual. Blood lactate
was chosen as an indicator for disturbance of the microcirculation
and urine output during the last two hours of the experiment
served as an indicator for parenchymal perfusion pressure and
renal function. IMD treatment resulted in a significant reduction
of MAP. Notably, this decrease in blood pressure did not impact
blood lactate levels and urinary output, suggesting that systemic
microcirculation and renal perfusion were not relevantly compro-
mised (Fig S3). In additional experiments, an increased IMD dose
(0.075 mg/kg/h) resulted in blood lactate levels of 56 +/- 13 mg/
dl (n=4) indicating a significant deterioration of the microcircu-
lation despite a constant mean arterial blood pressure between 60–
65 mmHg throughout the experiment (data not shown). Blood
lactate levels in the control group were 37 +/- 5 mg/dl
respectively. Thus, the dose of 0.025 mg/kg/h IMD was chosen,
which reduced hyperpermeability while severe side effects due to
haemodynamic alterations were not evident.
Peripheral Oxygen Saturation in VILI was Slightly
Improved by IMD Treatment
Improvement of oxygenation is not necessarily associated with
improved survival in ARDS. However, loss of oxygenation
VILI and IMD
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oxygenation would provide evidence for the efficacy of IMD
associated reduction of VILI. Therefore, peripheral oxygen
saturation was measured continuously throughout the experiments
by pulse oxymetry, and pO2 was determined in arterial blood by
a routine blood gas analyzer.
IMD treated individuals showed significantly (p,0.001) but
only slightly improved peripheral oxygen saturation as compared
to untreated ventilated mice throughout the observation period
(Fig. 5A). However, following a final recruitment manoeuvre there
was no detectable difference between groups regarding SpO2 and
P/F ratio (Fig. 5B; Fig. 5C).
IMD Reduced Pulmonary Vasoconstriction
With regard to the missing improvement in oxygenation despite
barrier-stabilizing properties of IMD, we hypothesized that
vasodilatory properties known for IMD might counteract re-
duction of lung injury by an increase of ventilation/perfusion
mismatch. Indeed, hypoxic pulmonary vasoconstriction (HPV)
was reduced by IMD in murine precision cut lung slices of mice
(Fig. 6A). Further, IMD dose dependently reduced pulmonary
vasoconstriction evoked by the thromboxane receptor agonist
U46619 in isolated ventilated and perfused mouse lungs (Fig. 6B).
Thus, an IMD related increase of the ventilation/perfusion
mismatch possibly overrode improvement of barrier function
due to IMD treatment.
IMD did not Reduce Inflammation in VILI
Activation of the innate immune system plays a key role in the
pathophysiology of VILI, and dampening this response can
ameliorate VILI. However, interference with pathways of the
innate immune system may render ARDS patients even more
susceptible towards infections and cause unfavorable outcomes.
Thus, we aimed to determine the impact of IMD on crucial innate
immune responses in VILI. We analyzed leukocyte counts in the
BAL fluid, lung homogenate and blood and quantified cytokines in
lungs and blood. VILI evoked recruitment of neutrophils and Gr-
1high monocytes as detected in BAL fluid and in lung
homogenates. IMD did not impact pulmonary recruitment of
neutrophils or Gr-1high monocytes in VILI (Fig. 7). VILI
provoked blood leukocytosis with elevated numbers of monocytes
and neutrophils, which was not modified by IMD treatment
(Fig. 7). VILI increased pulmonary levels of IL-1b, IL-18, IL-6,
KC, MIP-1a, MIP-2, MCP-1 and IL12p40, while IL-10 levels
remained at baseline. IMD treatment did not alter pulmonary
cytokine profiles (Fig. 8A). Also, plasma levels of IL-18, IL-6, KC,
MIP-2, MCP-1, IL-12p40 and IL-10 were increased in mice
ventilated for 6 h. IL-1b levels remained at baseline. IMD did not
alter levels of measured plasma cytokines (Fig. 8B). Notably, in
additional experiments with a higher dosage of IMD (0.075 mg/
kg/h) we observed a trend towards reduced neutrophil counts in
the BAL fluid (p=0.0571, n=4) and reduced monocyte counts in
blood (p=0.0286 n=4) due to IMD treatment. As outlined
above, 0.075 mg/kg/h IMD probably tended to cause deteriora-
tion of microcirculation and was therefore not used for further
investigations.
Discussion
In the current study, IMD enhanced endothelial barrier
function in vitro and diminished lung hyperpermeability, but not
pulmonary and systemic inflammation in a clinically relevant
mouse model of VILI.
Impairment of endothelial barrier function is a hallmark of
VILI and ARDS, leading to development of lung edema,
surfactant dysfunction and deterioration of pulmonary gas
exchange [6]. Particularly preinjured lungs are susceptible to
VILI, and VILI may contribute to lung injury in ARDS patients
despite lung protective ventilation strategies [4,5]. A pharmaco-
logic approach to reduce pulmonary permeability in addition to
lung protective ventilation strategies thus may be a promising
adjuvant therapeutic strategy to minimize VILI in ARDS patients.
IMD is an endogenous CRLR ligand that mediated endothelial
barrier stabilizing effects in vitro and in an isolated lung model of
hydrostatic lung edema [10,11]. In mechanically ventilated mice,
we investigated the regulation of IMD and its receptor complex
composed of CRLR and one of the auxiliary proteins RAMP1, 2
and 3, which are mandatory for efficient CRLR signalling [8,9].
Expression of IMD, CRLR and RAMP1 and 2 were not affected
by MV, whereas RAMP3 expression was significantly reduced.
Previous studies suggested that IMD predominantly signals
through receptor complexes composed of CRLR and RAMP2
or 3 [8,9]. Thus, the observed down regulation of RAMP3 may
indicate reduced efficacy of endogenous IMD signalling in VILI,
and treatment with exogenous IMD may restore or further amplify
endogenous barrier stabilizing IMD effects in VILI.
Indeed, in the currently employed mouse model, continuously
infused IMD markedly reduced lung permeability in VILI. To the
best knowledge of the authors this study is the first providing
evidence for pulmonary permeability reduction due to exogenous
IMD in VILI. Mechanisms suggested to be responsible for the
barrier stabilizing properties of CRLR signalling include increase
of intracellular cAMP, leading to a protein kinase A dependent
inhibition of myosin light chain phosphorylation and stabilization
of intercellular junctions, finally leading to reduced endothelial
intercellular gap formation [10,11,24,25]. This mechanism,
originally studied by CRLR stimulation with AM has been
confirmed in a murine VILI model, in models of ALI and in
isolated rat intestine exposed to bacterial toxin [7,24,26,27].
Despite marked reduction of VILI-induced pulmonary perme-
ability in IMD treated individuals, oxygenation was not improved.
This contradictory finding may be partly explained by vasodilatory
effects displayed by IMD. Specifically in the current study,
increased pulmonary vascular resistance due to thromboxane
receptor stimulation was reduced by IMD in isolated perfused and
ventilated mouse lungs, and HPV in murine lung tissue slices was
diminished by IMD. Although direct evidence is not provided by
the current study, it is tempting to speculate that reduction of
pulmonary vascular resistance by IMD resulted in ventilation/
perfusion (V/Q) mismatch and increment of pulmonary shunt
perfusion, probably masking improved oxygenation capacity due
to reduced oedema formation in IMD treated individuals.
Pulmonary hyperinflammation is a central feature of VILI and
contributes to lung permeability [6]. Previously, the CRLR ligand
adrenomedullin ameliorated inflammatory responses in polymi-
crobial sepsis suggesting that CRLR signalling may mediate
immunomodulating effects [28,29]. In hyperoxic VILI, we
observed ameliorated leukocyte infiltration into the alveolar space
due to AM treatment [7], which was not evident in the current
study using 0.025 mg/kg/h IMD. Also, cytokine production was
unaltered by IMD. Notably in preliminary experiments, IMD in
a higher dosage (0.075 mg/kg/h) reduced neutrophil counts in the
BAL fluid of IMD treated mice subjected to VILI as compared to
solvent treated controls by trend (p=0.057; n=4; data not shown
in detail). Concurrently, neutrophil counts were significantly
reduced in the blood and increased in lung tissue (p,0.05;
n=4; data not shown in detail), probably as a result of leukocyte
VILI and IMD
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levels were elevated in these mice. In line, IMD has been reported
to lower systemic blood pressure in rodents [8,13,30]. In
preliminary experiments (n=4), 0.075 mg/kg/h IMD lowered
mean arterial blood pressure and compromised systemic micro-
circulation. However, treatment with 0.025 mg/kg/h IMD
reduced MAP only moderately and did not result in compromised
systemic microcirculation or relevant reduction of end organ
perfusion pressure as indicated by comparable blood lactate levels
and urine output in both groups. Thus, IMD most likely reduced
endothelial gap formation in VILI by inflammation-independent
mechanisms in the current study, which may hold relevant clinical
benefits. First, in ventilated ARDS patients with sepsis or severe
pneumonia, hyperinflammation may override anti-inflammatory
properties of pharmacologic therapies. Second, limiting central
mechanisms of the innate immune response may compromise host
defence against invading pathogens and thereby pave the way for
secondary bacterial infections.
In conclusion, the endogenous CRLR ligand peptide IMD
reduced pulmonary vascular leakage in a clinically relevant mouse
model of VILI. Reduction of lung permeability was not
accompanied by reduced pulmonary or systemic inflammation.
However, regarding oxygenation capacity IMD may counteract
reduction of lung edema by increasing V/Q mismatch.
Supporting Information
Figure S1 Preabsorption of the IMD antibody with
mouse IMD (1–47) resulted in almost complete absence
of labelling, suggesting high specificity of the primary
antibody. Both tissue sections were cut from the same specimen
and processed simultaneously. Images were taken at the same
exposure time (190 ms).
(TIF)
Figure S2 Double labelling with LEA to depict the
epithelial lining of the alveolus in non ventilated lungs.
The merged image also includes DNA labelling with DAPI to
highlight cellular nuclei. There is little overlap of LEA binding to
alveolar type I cells with IMD- or CRLR-immunoreactivity. Arrows
in the merged image point to LEA-binding epithelial stretches
without IMD- or CRLR-immunoreactivity.
(TIF)
Figure S3 Mice were ventilated with a tidal volume of
12 ml/kg for 6 h and treated with IMD 0.025 mg/kg*h
(6 h vent.+IMD) or solvent (6 h vent). A) Mean arterial
blood pressure (MAP) was monitored. MAP was lower in IMD
treated individuals B) Lactate levels quantified at the end of the
experiment and C) urine output were not different between groups
(***p,0.001; n=15).
(TIF)
Table S1
(DOC)
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